統合された、マルチモーダル痛みタスクのバッテリーを使用痛みの検出と許容閾値を決定

Executive Industry Relevance

This multi-modal pain task battery enables comprehensive profiling of analgesic candidates across distinct nociceptive pathways, supporting mechanistic de-risking in early discovery. By integrating electrical, pressure, thermal, and inflammatory pain modalities with conditioned pain modulation, the approach provides predictive confidence in target validation and analgesic mechanism characterization. The reproducible, rapid-throughput design supports iterative compound screening and go/no-go decisions in analgesic portfolio management.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses across multiple pain pathways to clarify target engagement and functional validity.
• Operational Value: Enables biological de-risking by detecting analgesic effects on detection thresholds, tolerance, and conditioned pain modulation.
• Predictive Value: Supports portfolio triage through quantitative, repeatable endpoints predictive of analgesic efficacy.

Screening & Assay Development

• Scientific Value: Prepares validated human pain models for standardized, quantitative assessment of compound effects.
• Operational Value: Ensures assay reproducibility and scalability across electrical, pressure, cold, and thermal pain modalities.
• Translational Value: Delivers multi-dimensional pain phenotyping to enable reliable compound evaluation and mechanism classification.

Translational & Preclinical Research

• Scientific Value: Aligns with disease-relevant pain mechanisms through UVB-induced hyperalgesia and conditioned pain modulation paradigms.
• Operational Value: Supports translational continuity from target validation to preclinical efficacy testing via repeated, low-burden assessments.
• Risk Mitigation: Enhances predictive confidence in analgesic profiling by capturing complex, clinical-like pain phenotypes.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation through lead identification to preclinical efficacy, enabling iterative analgesic profiling across mechanism classes.

• Discovery Biology: Supports hypothesis testing and pathway clarification by isolating contributions of distinct nociceptive systems to analgesic response.
• Screening: Delivers assay readiness through standardized, quantitative pain threshold and tolerance measurements across modalities.
• Analytics: Provides pain detection threshold, area under the VAS curve, and post-test VAS ratings as quantitative readouts for cross-condition comparison.
• Translational Research: Connects to preclinical continuity via disease-relevant inflammatory and conditioned pain models that mirror clinical pain complexity.
• Enterprise Reuse: Functions as a reusable capability for iterative analgesic characterization across projects and therapeutic areas.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in target validation, reduction of mechanistic ambiguity, and pathway-specific analgesic profiling.
• Operational Value: Standardization, reproducibility, and scalability of multi-modal pain assessment with minimal subject burden.
• Strategic Value: Improved go/no-go decisions, capital efficiency, and reduced late-stage biological risk in analgesic development.
• Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on comprehensive analgesic mechanism profiling.

Implementation Considerations

• Requires expertise in psychophysical pain assessment and standardized stimulus delivery.
• Depends on instrumentation including constant current stimulators, electro-pneumatic regulators, thermodes, and UVB lamps.
• Necessitates cross-team standardization of pain scale training, electrode placement, and stimulus timing protocols.
• Involves adaptation considerations across skin types, pain sensitivity profiles, and contraindications for thermal or ischemic stimuli.
• Limited by subject availability and the need for consistent environmental control during repeated testing sessions.

Biopharma FAQs